natgillin/translations-raw huggingface dataset:
A hydroxylamine compound represented by formula (III) or salt thereof: in formula (III), Cy1 represents a C6-10 aryl group or a heterocyclyl group; 
Spoj hidroksilamina, naznačen time, da je predstavljen formulom (III) ili njegova sol: [image] gdje u formuli (III), Cy1 predstavlja (C6-10)-aril-skupinu ili heterociklil-skupinu;
and R11 of Cy1 may independently form a ring, or bond together to form a ring, or bond with the atoms constituting Cy1 to form a ring; 
i R11 od Cy1, mogu neovisno tvoriti prsten, ili su vezani zajedno za tvorbu prstena, ili su za tvorbu prstena, vezani s atomima koji sačinjavaju Cy1;
n represents the number of R11 and represents an integer of 0 to 5, when n is 2 or more, R11s may be the same and different. 
n predstavlja broj skupina R11 i predstavlja cijeli broj od 0 do 5, a kada m je 2 ili više, tada skupine R11 mogu biti iste ili različite.
A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and one or more pharmaceutically acceptable carriers, diluents and excipients. 
Farmaceutski sastav obuhvaća terapijski učinkovitu količinu tvari iz patentnog zahtjeva 1 i jedan ili više farmaceutski prihvatljivih nosača, diluenata i ekscipijenasa.
A compound of any one of claims 1 to 7, or a pharmaceutically acceptable acid addition salt thereof for the treatment of neurodegenerative disorders. 
Tvar iz patentnog zahtjeva 1 ili njena farmaceutski prihvatljiva sol dobivena adicijom kiseline za uporabu u liječenju neurodegenerativnih poremećaja u sisavaca.
A compound of any one of claims 1 to 7, or a pharmaceutically acceptable acid addition salt thereof for the treatment of psychoses, impotence, renal failure, heart failure, hypertension, cognitive impairment, restless legs syndrome (RLS), periodic limb movement disorder (PLMD), movement disorders, poverty of movement, dyskinetic disorders, gait disorders, intention tremor or dyskinesias in a mammal, such as a human subj ect. 
Tvar iz patentnog zahtjeva 1 ili njena farmaceutski prihvatljiva sol dobivena adicijom kiseline za uporabu u liječenju psihoze, impotencije, zatajenja bubrega, zatajenja srca, hipertenzije, kognitivnog oštećenja, sindroma nemirnih nogu (RLS), periodičnog poremećaja pokreta udova (PLMD), poremećaja pokreta, oskudnosti pokreta, diskinetičkih poremećaja, poremećaja hoda, ili intencijskog tremora u sisavaca.
A compound of any one of claims 1 to 7, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of depression, bipolar disorder and anxiety. 
Tvar iz patentnog zahtjeva 1, ili njena farmaceutski prihvatljiva sol dobivena adicijom kiseline, za uporabu u liječenju depresije, bipolarnog poremećaja i tjeskobe u sisavaca.
A compound of any one of claims 1 to 7, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of cognitive impairment associated with a disorder or disease selected from schizophrenia, Parkinson's Disease, dementia such as AIDS dementia, anxiety disorder, age associated memory impairment, depression, including major depression, in particular in elderly, Alzheimer's Disease, attention deficit hyperactivity disorder (ADHD) or post-traumatic stress disorder (PTSD). 
Tvar iz patentnog zahtjeva 1, ili njena farmaceutski prihvatljiva sol dobivena adicijom kiseline, za uporabu u liječenju kognitivnog oštećenja povezanog s poremećajem ili bolesti odabranim između shizofrenije, Parkinsonove bolesti, demencije, tjeskobnog poremećaja, starosnog oštećenja pamćenja, depresije, Alzheimerove bolesti, hiperaktivnog poremećaja s nedostatkom pažnje (ADHD) ili posttraumatskog stresnog poremećaja (PTSD) u sisavaca.
injecting gaseous carbon dioxide and a slurry into the feed water, wherein the slurry comprises micronized calcium carbonate, wherein the calcium carbonate has a particle size from 0.1 to 100 µm. 
injektiranje plinovitog ugljik dioksida i mulja u ulaznu vodu, pri čemu mulj sadrži mikronizirani kalcij karbonat, gdje kalcij karbonat ima veličinu čestica od 0.1 do 100 µm i HCl netopljivi sadržaj od 0.05 do 1.5 wt.-% zasnovano na ukupnoj masi mikroniziranog kalcij karbonata.
The process of any of the previous claims, wherein the slurry comprises further minerals containing magnesium, potassium or sodium, preferably magnesium carbonate, magnesium sulfate, potassium hydrogen carbonate, or sodium hydrogen carbonate. 
Postupak prema bilo kojem od prethodnih zahtjeva, pri čemu mulj sadrži daljnje minerale koji sadrže magnezij, kalij ili natrij, poželjno magnezij karbonat, kalcij magnezij karbonat, poput dolomitskog vapnenca, vapnenačkog dolomita, dolomita ili polu-spaljenog dolomita, magnezij oksid poput spaljenog dolomita, magnezij sulfat, kalij hidrogen karbonat, ili natrij hidrogen karbonat.
Use of a micronized calcium carbonate in form of a slurry for remineralization of water, the remineralization comprising a step of injecting gaseous carbon dioxide into feed water, wherein the calcium carbonate has a particle size from 0.1 to 100 µm. 
Uporaba mikroniziranog kalcij karbonata u obliku mulja za remineralizaciju vode, remineralizacija sadrži korak injektiranja plinovitog ugljik dioksida u ulaznu vodu, pri čemu kalcij karbonat ima veličinu čestica od 0.1 do 100 µm i HCl netopljivi sadržaj od 0.05 do 1.5 wt.-% zasnovano na ukupnoj masi mikroniziranog kalcij karbonata.
immersing the strands of wood in a watery solution of a flame retardant chemical composition, 
uranjanje drvenih vlakana u vodenu otopinu kemijskog sredstva za usporavanje plamena,
The method according to claim 2, wherein the step (c) of separating the strands from each other comprises stirring the mixture of strands and watery solution of a flame retardant chemical composition. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time, da korak (c) međusobno odvajanje vlakana uključuje miješanje smjese vlakana i vodene otopine kemijskog sredstva za usporavanje plamena.
forming at least two layers of strands, wherein the strands of each layer are substantially parallel to each other, 
oblikovanje najmanje dva sloja vlakana, pri čemu su vlakna svakog sloja u biti međusobno paralelna,
subjecting the strands of wood to an air-jet, which has a direction that is substantially opposite to the force of gravity on the strands. 
podvrgavanje drvenih vlakana djelovanju zračnog mlaza, koji ima smjer u biti suprotan djelovanju sile gravitacije na vlakna.
The method according to any of the preceding claims, wherein the flame retardant chemical composition comprises a phosphate compound, such as an ammonium phosphate. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da kemijsko sredstvo za usporavanje plamena sadržava fosfatni spoj, na primjer amonijev fosfat.
A monoclonal antibody having the ability of binding to CLD18A2 and mediating killing of cells expressing CLD18A2, wherein the antibody binds to an epitope localized on the CLD18A2-loop1 or the CLD18A2-loopD3 and wherein killing is induced by binding of the antibody to CLD18A2 expressed by said cells, wherein the antibody mediates killing of cells by inducing complement dependent cytotoxicity (CDC) mediated lysis and/or antibody dependent cellutar cytotoxicity (ADCC) mediated lysis. 
Monoklonsko antitijelo koje ima sposobnost vezanja za CLD18A2 i posredovanja u ubijanju stanica koje eksprimiraju CLD18A2, pri čemu se antitijelo veže za epitop lokaliziran na CLD18A2-petlji1 ili CLD18A2-petljiD3 i pri čemu je ubijanje inducirano vezanjem antitijela za CLD18A2 eksprimiranog od strane navedenih stanica, pri čemu antitijelo posreduje u ubijanju stanica indukcijom lize posredovane preko citotoksičnosti ovisne od komplementa (CDC) i/ili lize posredovane preko stanične citotoksičnosti zavisne od antitijela (ADCC).
The antibody of claims 1 or 2 wherein said cells expressing. CLD18A2 are cancer cells, wherein the cancer cells are preferably selected from the group consisting of tumorigenic gastric, esophageal, pancreatic and lung cancer cells. 
Antitijelo prema patentnim zahtjevima 1 ili 2 naznačeno time što su navedene stanice koje eksprimiraju CLD18A2 kancerske stanice, pri čemu su kancerske stanice poželjno izabrane iz grupe koja se sastoji od tumorogenih stanica kancera želuca, jednjaka, pankreasa i pluća.
The antibody of claim 1 which comprises a light chain variable region (VL) comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 138, 139, 140, 141, 142, 143, 144, 145, 146, and a fragment thereof. 
Antitijelo prema patentnom zahtjevu 1 koje sadrži varijabilnu regiju lakog lanca (VL) koja sadrži aminokiselinsku sekvencu izabranu iz grupe koja se sastoji od SEQ ID NO: 138, 139, 140, 141, 142, 143, 144, 145, 146 i fragmenta istih.
An antibody of any one of claims 1 to 5, a conjugate of claim 7 or a pharmaceutical composition of claim 8 for use in a method of treating or preventing a disease or disorder involving cells expressing CLD18A2. 
Antitijelo prema bilo kojem od patentnih zahtjeva 1 do 20, konjugat prema patentnom zahtjevu 22 ili farmaceutska kompozicija prema patentnom zahtjevu 23 za uporabu u postupku liječenja ili prevencije bolesti ili poremećaja koja/koji uključuje stanice koje eksprimiraju CLD18A2.
The antibody, conjugate or pharmaceutical composition for use according to claim 6 wherein the disease or disorder is a tumor-related disease, wherein the tumor-related disease preferably is selected from the group consisting of breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, colorectal cancer, hepatic cancer, head-neck cancer, cancer of the gallbladder, and the metastases thereof. 
Antitijelo, konjugat ili farmaceutska kompozicija za uporabu prema patentnom zahtjevu 25 gdje, bolest ili poremećaj je bolest povezana sa tumorom, pri čemu je bolest povezana sa tumorom poželjno izabrana iz grupe koja se sastoji od kancera dojke, kancera želuca, kancera jednjaka, kancera pankreasa, kancera pluća, kancera jajnika, kancera debelog crijeva, kolorektalnog kancera, kancera jetre, kancera glave i vrata, kancera žučne vrečice i njihovih metastaza.
The antibody, conjugate or pharmaceutical composition for use according to claim 25 or 26, wherein the method further comprises treating with a chemotherapeutic agent, radiation, or a cytokine. 
Antitijelo, konjugat ili farmaceutska kompozicija za uporabu prema patentnom zahtjevu 25 ili 26, pri čemu postupak dalje sadrži liječenje kemoterapeutskim sredstvom, zračenjem ili citokinom.
The antibody, conjugate or pharmaceutical composition for use according to claim 8, wherein the chemotherapeutic agent is selected from the group consisting of doxorubicin, cisplatin, taxotere, 5-fluoruracil, methotrexat, gemcitabin and cyclophosphamide. 
Antitijelo, konjugat ili farmaceutska kompozicija za uporabu prema patentnom zahtjevu 27, pri čemu je kemoterapeutsko sredstvo izabrano iz grupe koja se sastoji od doksorubicina, cisplatina, taksotere, 5-fluorouracila, metotreksata, gemcitabina i ciklofosfamida.
The compound according to claim 1, wherein each of R5, R6, R7 and R8 may be same or different and is independently selected from the group consisting of hydrogen; hydroxy; C1-C4 alkyl; C1-C4 haloalkyl; C1-C4 alkoxy; C1-C4 haloalkoxy; C2-C5 alkanoyl; halogen; phenyl; cyano; nitro; amino; and carboxylic acid group; or R5 and R6 together with a carbon atom to which they are attached may form a carbonyl group (C=O) or thioxo group (C=S), or R7 and R8 together with a carbon atom to which they are attached may form a carbonyl group (C=O) or thioxo group (C=S), or racemate, or pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje svaki od R5, R6, R7 i R8 mogu biti jednaki ili različiti i nezavisno se izabiru iz grupe koja obuhvaća vodik; hidroksi; C1-C4 alkil; C1-C4 haloalkil; C1-C4 alkoksi; C1-C4 haloalkoksi; C2-C5 alkanoil; halogen; fenil; cijano; nitro; amino; i skupinu karboksilne kiseline; ili R5 i R6 zajedno s atomom ugljika na koji su spojen mogu formirati karbonilnu skupinu (C=O) ili tiokso skupinu (C=S), ili R7 i R8 zajedno s atomom ugljika na koji su spojeni mogu formirati karbonilnu skupinu (C=O) ili tiokso skupinu (C=S), ili njegov racemat ili farmaceutski prikladna sol.
The compound according to claim 1, wherein each of R1, R2, R3 and R4 may be same or different and is independently selected from the group consisting of hydrogen; hydroxy; C1-C4 alkyl; C1-C4 haloalkyl; unsubstituted or substituted C1-C4 alkoxy; C1-C4 haloalkoxy; halogen; phenyl; cyano; nitro; amino; carboxylic acid group; C2-C5 alkanoyl; C2-C5 alkoxycarbonyl; C2-C5 alkanoyloxy; C3-C10 mono or bicycloalkyl; C4-C11 cycloalkylalkyl; C6-C10 aryl;, saturated or unsaturated C3-C10 mono or polycarbocyclyl; and, saturated or unsaturated 3- to 10-membered mono or polyheterocyclyl containing 1 to 3 heteroatoms, provided that when X1 is nitrogen, R2 does not exist; when X2 is nitrogen, R3 does not exist; and when X3 is nitrogen, R4 does not exist, or racemate, or pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje svaki od R1, R2, R3 i R4 mogu biti jednaki ili različiti i nezavisno se izabiru iz grupe koja obuhvaća vodik; hidroksi; C1-C4 alkil; C1-C4 haloalkil; nesupstituirani ili supstituirani C1-C4 alkoksi; C1-C4 haloalkoksi; halogen; fenil; cijano; nitro; amino; skupinu karboksilne kiseline; C2-C5 alkanoil; C2-C5 alkoksikarbonil; C2-C5 alkanoiloksi; C3-C10 mono ili bicikloalkil; C4-C11 cikloalkilalkil; C6-C10 aril; zasićeni ili nezasićeni C3-C10 mono ili polikarbociklil; i zasićeni ili nezasićeni 3- do 10-eročlani mono ili poliheterociklil koji sadrži 1 do 3 heteroatoma, uz uvjet da kada je X1 dušik, R2 ne postoji; kada je X2 dušik, R3 ne postoji; i kada je X3 dušik, R4 ne postoji, ili njegov racemat ili farmaceutski prikladna sol.
The compound according to claim 1, wherein each of R1, R2, R3 and R4 may be same or different and is independently selected from the group consisting of hydrogen; C1-C4 alkyl; C1-C4 haloalkyl; halogen; phenyl; cyano; and, saturated or unsaturated 3- to 10-membered mono or polyheterocyclyl containing 1 to 3 heteroatoms; or each of R1-R2, R2-R3 and R3-R4 pairs may be independently fused to form a saturated or unsaturated 5- to 6-membered carbocycle, provided that when X1 is nitrogen, R2 does not exist; when X2 is nitrogen, R3 does not exist; and when X3 is nitrogen, R4 does not exist, or racemate, or pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje svaki od R1, R2, R3 i R4 mogu biti jednaki ili različiti i nezavisno se izabiru iz grupe koja obuhvaća vodik; C1-C4 alkil; C1-C4 haloalkil; halogen; fenil; cijano; i zasićeni ili nezasićeni 3- do 10-eročlani mono ili poliheterociklil koji sadrži 1 do 3 heteroatoma; ili svaki od R1-R2, R2-R3i R3-R4 parova mogu biti nezavisno fuzionirani da formiraju zasićeni ili nezasićeni 5- do 6-eročlani karbocikl, uz uvjet da kada je X1 dušik, R2 ne postoji; kada je X2 dušik, R3 ne postoji; i kada je X3 dušik, R4 ne postoji, ili njegov racemat ili farmaceutski prikladna sol.
reducing Formula VII compound to obtain Formula VI compound, 
redukcija spoja Formule VII da se dobije spoj Formule VI,
cyclizing the obtained Formula VI compound with Formula V compound to obtain Formula IV compound, and 
ciklizacija dobivenog spoja Formule VI sa spojem Formule V da se dobije spoj Formule IV, i
peptide-bonding the obtained Formula IV compound with Formula III compound to obtain Formula II compound: wherein, in Formulae II to VII, X1, X2, X3, R1, R2, R3, R4, R5, R6, R7, R8 and Y are the same as defined in claim 1, and Z represents a reactive leaving group. 
peptidno vezanje dobivenog spoja Formule IV sa spojem Formule III da se dobije spoj Formule II: [image] [image] [image] gdje, u Formulama II do VII, X1, X2, X3, R1, R2, R3, R4, R5, R6, R7, R8 i Y su jednaki onome kako je definirano u zahtjevu 1, i Z predstavlja reaktivnu odlazeću skupinu.
halogenating Formula VII compound to obtain Formula X compound and then reacting the obtained Formula X compound with Formula IX compound to obtain Formula VIII compound, or conducting a Mitsunobu reaction of Formula VII compound and Formula IX compound to obtain Formula VIII compound, 
halogeniranje spoja Formule VII da se dobije spoj Formule X i zatim reakcija dobivenog spoja Formule X sa spojem Formule IX da se dobije spoj Formule VIII, ili provođenje Mitsunobu reakcije spoja Formule VII i spoja Formule IX da se dobije spoj Formule VIII,
cyclizing the obtained Formula VIII compound to obtain Formula IV compound, and 
ciklizacija dobivenog spoja Formule VIII da se dobije spoj Formule IV, i
peptide-bonding the obtained Formula IV compound with Formula III compound to obtain Formula II compound: wherein, in Formulae II to X, X1, X2, X3, R1, R2, R3, R4, R5, R6, R7, R8 and Y are the same as defined in claim 1, R12 is a non-hydrogen substituent, and R13 represents a reactive leaving group. 
peptidno vezanje dobivenog spoja Formule IV sa spojem Formule III da se dobije spoj Formule II: [image] [image] [image] gdje, u Formulama II do X,, X2, X3, R1, R2, R3, R4, R5, R6, R7, R8 i Y su jednaki onome kako je definirano u zahtjevu 1, R12 je supstituent koji nije, i
A method for preparing a compound of Formula XII, or racemate, or pharmaceutically acceptable salt thereof, comprising the step of amide-bonding Formula IV compound with Formula XIII compound in the presence of base: wherein, in Formulae IV, XII and XIII, X1, X2, X3, R1, R2, R3, R4, R5, R6, R7, R8 and Y are the same as defined in claim 1, Z represents a reactive leaving group. 
, X2, X3, R1, R2, R3, R4, R5, R6, R7, R8 i Y su jednaki onome kako je definirano u zahtjevu 1. Postupak pripreme spoja Formule XII, ili njegovog racemata ili farmaceutski prikladne soli, koji obuhvaća korak amidnog vezanja spoja Formule IV sa spojem Formule XIII u prisutnosti baze:
A pharmaceutical composition comprising an effective amount of the compound defined in any one of claims 1 to 17 or racemate, or pharmaceutically acceptable salt thereof as active ingredient, and pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži učinkovitu količinu spoja definiranog prema bilo kojem od zahtjeva 1 do 17 ili njegovog racemata ili farmaceutski prikladne soli kao djelatnu tvar, i farmaceutski prikladan nosač.
The pharmaceutical composition according to claim 24, wherein the gout disease is acute gouty arthritis, chronic gouty arthritis, tophus or gout nephrosis. 
Farmaceutski pripravak prema zahtjevu 24, gdje bolest gihta jest akutni urični artritis, kronični urični artritis, tofus ili giht nefroza.
Z is a radical selected from formulae: 
Z je radikal odabran od formula:
aryl is a homocycle selected from phenyl, naphthyl, acenaphthyl or tetrahydronaphthyl, each being optionally substituted with 1, 2 or 3 substituents, each substituent being independently selected from hydroxy, halo, cyano, nitro, amino, mono- or dialkylamino, alkyl, haloalkyl, alkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl, morpholinyl or mono- or dialkylaminocarbonyl; 
aril je homocikal odabran od fenila, naftila, acenaftila ili tetrahidronaftila, koji je svaki proizvoljno supstituiran s 1, 2 ili 3 supstituenata, te je svaki supstituent neovisno odabran od hidroksi, halo, cijano, nitro, amino, mono- ili dialkilamino, alkila, haloalkila, alkiloksi, karboksila, alkiloksikarbonila, aminokarbonila, morfolinila ili mono- ili dialkilaminokarbonila;
A compound according to any one of claims 1 and 2, characterized in that p is 1; Z is a radical of formula (a); R1 is bromo or methyl; R2 is methyloxy or phenyl; R3 is phenyl optionally substituted with methyloxy, or benzyl; q is 1; R4 and R5 each are methyl, ethyl or isopropyl, or R4 and R5 together with the nitrogen atom to which they are attached form a 4-thiomorpholino radical, a piperidino radical substituted with methyl at the 4-position or a piperazino radical substituted with benzyl at the 4-position; R6 is phenyl or benzofuranyl; and R7 is hydrogen. 
Spoj prema bilo kojem od zahtjeva 1 i 2, naznačen time da p je 1; Z je radikal s formulom (a); R1 je bromo ili metil; R2 je metiloksi ili fenil; R3 je fenil proizvoljno supstituiran s metiloksi, ili benzilom; q je 1; R4 i R5 su svaki metil, etil ili izopropil, ili R4 i R5 zajedno s dušikovim atomom na koji su vezani tvore 4-tiomorfolino radikal, piperidino radikal supstituiran s metilom na 4-položaju ili piperazino radikal supstituiran s benzilom na 4-položaju; R6 je fenil ili benzofuranil; i R7 je vodik.
A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as defined in any one of claims 1 to 6. 
Pripravak naznačen time da sadrži farmaceutski prihvatljiv nosač, te kao aktivni sastojak, terapijski učinkovitu količinu spoja kako je definirano u bilo kojem od zahtjeva 1 do 6.
a valve body (4) provided with means (5) for engagement with the lid (2) of the pressure cooking apparatus and crossed by a passage (6) for the steam generated by the pressure cooking apparatus; 
– tijelo ventila (4) koje sadrži element (5) za spajanje s poklopcem (2) uređaja za kuhanje pod tlakom i ima prolaz (6) za vodenu paru nastalu u uređaju za kuhanje pod tlakom;
a flow control element (7), which is arranged along said passage (6) and is associated detachably with said valve body (4); 
– element za kontrolu protoka (7), koji se nalazi duž navedenog prolaza (6) i odvojivo je povezan s navedenim tijelom ventila (4);
exit of the fuel duct (8) from the fuel filter and further magnetization of the fuel present in the fuel duct (8) due to at least one pair of magnets (14) placed directly in contact with said fuel duct (8) and situated in proximity to the system for injecting said fuel into the combustion chamber, having sign analogous to that induced in devices b, c; 
izlaska voda (8) za gorivo iz filtera goriva i daljeg magnetiziranja goriva prisutnog u vodu (8) za gorivo uslijed najmanje jednog para magneta (14) postavljenog direktno u kontaktu sa navedenim vodom (8) za gorivo i izvedenog u blizini sustava za ubrizgavanje navedenog goriva u komoru za sagorijevanje, gdje se magnetiziranje vrši znakom analognim onom induciranom u uređajima b, c;
magnetization of the water and/or of the liquid for cooling the engine due to at least one pair of magnets (16) placed directly on the tube of the cooling water (20) and capable of creating a charge with sign analogous to that induced in devices b, c, d; 
magnetiziranja vode i/ili rashladne tekućine motora uslijed najmanje jednog para magneta (16) postavljenog direktno na cijev za rashlađivanje vode (20) i sposobnog da formira naboj znaka analognog onom induciranom u uređajima b, c, d;
magnetization of the air fed to the internal combustion engine due to at least one pair of magnets (16), placed on the suction duct (17) in proximity to the engine and adapted to provide the air fed to the engine with a charge with sign opposite that provided to the fuel fed to the engine by means of devices b, c, d; 
magnetiziranja dovoda zraka do motora sa unutrašnjim sagorijevanjem uslijed najmanje jednog para magneta (16) postavljenog na usisni vod (17) u blizini motora i prilagođenog da osigura dovod zraka do motora sa nabojem suprotnog znaka u odnosu na onaj osiguran gorivu dopremljenom do motora pomoću uređaja b, c, d;
Method for treating the air-fuel mixture according to the preceding claims, wherein the magnets are made with ferromagnetic and/or paramagnetic elements, rare earth elements and especially the rare earth elements of neodymium and samarium cobalt. 
Postupak za tretiranje smjese zrak-gorivo prema prethodnim Zahtjevima, gdje su magneti izrađeni sa feromagnetnim i/ili paramagnetnim elementima, elementima rijetke zemlje a posebno elementima rijetke zemlje neodimij i samarij kobaltom.
Method according to the preceding claims, wherein the concave magnets can be integrated with rings of neodymium, ferrite and samarium cobalt. 
Postupak prema prethodnim Zahtjevima, gdje konkavni magneti mogu biti integrirani sa prstenovima od neodimija, ferita i samarij kobalta.
Zofenopril calcium crystalline form D comprising characteristic XRPD peaks at seven or more of 17.7, 18.0, 18.3, 19.2, 19.5, 19.9, 20.5, 21.9 and 23.1 ± 0.2 °2θ. 
Zofenopril kalcij kristaliničnog oblika D obuhvaća karakteristične XRPD pikove na sedam ili više od 17.7, 18.0, 18.3, 19.2, 19.5, 19.9, 20.5, 21.9 i 23.1 ± 0.2 °Ѳ.